Skip to main content

Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer

Cancer Chemotherapy and Pharmacology volume 68, pages 177–184 (2011)Cite this article

Abstract

Background

Both docetaxel-based and irinotecan-based chemotherapy has been demonstrated as active combination regimen in either first-line or second-line setting for metastatic gastric cancer. The purpose of this trial was to evaluate the two active regimens, docetaxel/cisplatin and FOLFIRI, as first- and second-line chemotherapy and to compare the sequence of the two regimens in terms of efficacy and tolerability.

Patients and methods

Eligible patients were randomized to receive one of the two treatment arms: Arm A-DP (docetaxel 75 mg/m2 D1, cisplatin 75 mg/m2 D1 repeated every 3 weeks) until progression or unacceptable toxicity as the first-line treatment which was followed by FOLFIRI (irinotecan 150 mg/m2 D1, leucovorin 100 mg/m2 D1, 5-fluorouracil 3,000 mg/m2 D1-2 for 48 h every 2 weeks) upon disease progression as second-line chemotherapy; Arm B-FOLFIRI as the first-line treatment until disease progression or unacceptable toxicity then followed by DP as the second-line treatment upon documented disease progression.

Results

Between April 2005 and Aug 2008, 58 patients were enrolled (Arm A, n = 28; Arm B, n = 30). Median follow-up was 38.2 months. The overall response rate (ORR) of the first-line chemotherapy was 25.0% with DP (Arm A1) and 13.3 with FOLFIRI (Arm B1) (P = 0.322). The tumor control rate (TCR) of first-line chemotherapy was 82.1% with DP and 66.7% with FOLFIRI (P = 0.209). The median first progression-free survival (1st PFS) was 4.3 months with DP and 3.4 months with FOLFIRI (P = 0.547). The overall response rate of second-line chemotherapy was 20.0% with FOLFIRI (Arm A2) and 27.2% with DP (Arm B2) (P = 0.296). The tumor control rate of second-line chemotherapy was 46.7% with FOLFIRI and 50.0% with DP. The median second progression-free survival (2nd PFS) was 8.1 months with Arm A and 6.7 months with Arm B (P = 0.865). The median overall survival was 12.5 months (95% CI 8.17–16.83) in Arm A and 13.4 months (95% CI 9.99–16.81) in Arm B (P = 0.674). In safety profile, the incidence of neutropenic fever was comparable among the 4 arms ranging from 0 to 3.9%.

Conclusions

The ORR, TCR of Arm A (DP → FOLFIRI) were not different from those of Arm B (FOLFIRI → DP). There was no statistically significant difference in 1st PFS, 2nd PFS, and OS of both arms. Although the trial was terminated early due to poor patient accrual, we found that both DP and FOLFIRI regimens were tolerable with comparable efficacies regardless of the sequence administered.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. National Cancer Information Center, available online at http://www.cancer.go.kr/cms/statics/incidence/index.html (Accessed 11 Sept 2009)

  2. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E (2005) Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23:5660–5667

    PubMed  Article  CAS  Google Scholar 

  3. Bouche O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsene D, Paitel JF, Guerin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C (2004) Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study–FFCD 9803. J Clin Oncol 22:4319–4328

    PubMed  Article  CAS  Google Scholar 

  4. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P (1999) Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical co-operative group. Br J Cancer 79:1522–1530

    PubMed  Article  CAS  Google Scholar 

  5. Kim H, Park JH, Bang SJ, Kim DH, Cho HR, Kim GY, Min YJ (2005) A phase II study of docetaxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU/platinum treatment. Jpn J Clin Oncol 35:727–732

    PubMed  Article  Google Scholar 

  6. Kim SG, Oh SY, Kwon HC, Lee S, Kim JH, Kim SH, Kim HJ (2007) A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer. Jpn J Clin Oncol 37:744–749

    PubMed  Article  Google Scholar 

  7. Kim SH, Lee GW, Il Go S, Cho SH, Kim HJ, Kim HG, Kang JH (2010) A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen. Am J Clin Oncol. doi:10.1097/COC.0b013e3181bead7b

  8. Kim ST, Kang WK, Kang JH, Park KW, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Park K (2005) Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer. Br J Cancer 92:1850–1854

    PubMed  Article  CAS  Google Scholar 

  9. Lorizzo K, Fazio N, Radice D, Boselli S, Ariu L, Zampino MG, Nole F, Magni E, Ardito R, Minchella I, Rocca A, Di Meglio G, Squadroni M, de Braud F (2009) Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer. Cancer Chemother Pharmacol 64:301–306

    PubMed  Article  CAS  Google Scholar 

  10. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S (2003) Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan clinical oncology group study (JCOG9205). J Clin Oncol 21:54–59

    PubMed  Article  CAS  Google Scholar 

  11. Ozdemir NY, Abali H, Oksuzoglu B, Budakoglu B, Uncu D, Guler T, Odabasi H, Zengin N (2009) The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. Med Oncol

  12. Park KW, Ahn JS, Park YS, Lee J, Kang JH, Park JO, Lim HY, Im YH, Kang WK, Park K, Lee SI (2007) Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer. Cancer Chemother Pharmacol 59:17–21

    PubMed  Article  CAS  Google Scholar 

  13. Park SH, Kang WK, Lee HR, Park J, Lee KE, Lee SH, Park JO, Kim K, Kim WS, Chung CW, Im YH, Lee MH, Park CH, Park K (2004) Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen. Am J Clin Oncol 27:477–480

    PubMed  Article  CAS  Google Scholar 

  14. Park SH, Nam E, Park J, Cho EK, Shin DB, Lee JH, Lee WK, Chung M, Lee SI (2008) Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer. Ann Oncol 19:729–733

    PubMed  Article  CAS  Google Scholar 

  15. Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Koberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F (2007) Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the swiss group for clinical cancer research. J Clin Oncol 25:3217–3223

    PubMed  Article  CAS  Google Scholar 

  16. Seo MD, Lee KW, Lim JH, Yi HG, Kim DY, Oh DY, Kim JH, Im SA, Kim TY, Lee JS, Bang YJ (2008) Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer. Jpn J Clin Oncol 38:589–595

    PubMed  Article  Google Scholar 

  17. Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Lee SS, Lee JS, Kang YK (2008) Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane. Am J Clin Oncol 31:151–156

    PubMed  Article  CAS  Google Scholar 

  18. Tomasello G, Chiesa MD, Buti S, Brighenti M, Negri F, Rovere RK, Martinotti M, Buononato M, Brunelli A, Lazzarelli S, Donati G, Passalacqua R (2010) Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen. Tumori 96:48–53

    PubMed  CAS  Google Scholar 

  19. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991–4997

    PubMed  Article  Google Scholar 

  20. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903–2909

    PubMed  Article  CAS  Google Scholar 

  21. Yun J, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK (2010) A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. Eur J Cancer 46:885–891

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-dong Kangnam-ku, Seoul, 135-710, Korea

    Jung A. Kim, Jeeyun Lee, Boram Han, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim & Won Ki Kang

  2. Division of Hematology-Oncology, Department of Medicine, Seoul Paik Hospital, Inje University School of Medicine, Seoul, Korea

    Jung A. Kim

Authors
  1. Jung A. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeeyun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Boram Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Se Hoon Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joon Oh Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Young Suk Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ho Yeong Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Won Ki Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Won Ki Kang.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kim, J.A., Lee, J., Han, B. et al. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer. Cancer Chemother Pharmacol 68, 177–184 (2011). https://doi.org/10.1007/s00280-010-1452-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-010-1452-4

Keywords

  • FOLFIRI
  • Docetaxel
  • Advanced gastric cancer
  • DP